ALPMF - Astellas Roche Diabetes Care team up to integrate Accu-Chek with BlueStar app
2023-03-29 04:41:23 ET
- Astellas Pharma ( OTCPK:ALPMF ) ( OTCPK:ALPMY ) is collaborating with Roche Diabetes Care Japan to develop and commercialize Roche's Accu-Chek Guide Me blood glucose monitoring system as a combined product with an app called BlueStar.
- Astellas said the BlueStar app, which is developed by Welldoc, is an FDA-cleared digital health solution for patients with diabetes and is marketed in the U.S. and Canada.
- Astellas and Welldoc are jointly developing BlueStar in Japan.
- The combined medical product, which is being developed in Japan, is expected to help patients manage diabetes by capturing, storing, and transmitting blood glucose data received from Roche Diabetes' — a unit of Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) — Accu-Chek and track medication, diet, activity and exercise in Welldoc's BlueStar app.
- The product is also expected to help diabetes self-management via an algorithm, made using AI, and personalized digital coaching messages aimed at building better habits over time.
- Astellas noted that it is responsible for the clinical trials of the combined medical product, and the studies are expected to start in 2023.
For further details see:
Astellas, Roche Diabetes Care team up to integrate Accu-Chek with BlueStar app